Press Releases
Publications & Presentations
Events
Press Releases
August 15, 2019
Combined company uniquely suited to drive precision oncology forward with RNA technologies to identify oncology drug responder populations Durham, NC, August 15, 2019 – GeneCentric Therapeutics, Inc. today announced that it has…
August 9, 2019
Partners to initiate Second Phase of R01-Awarded Research Durham, NC, August 9, 2019 – GeneCentric Therapeutics, Inc. today announced that it has entered the second phase of an academic-industry collaboration with Jose…
June 3, 2019
GeneCentric Therapeutics will present the first data on novel response signatures for metastatic, muscle invasive bladder cancer (MIBC) treatments by applying its proprietary, RNA-sequencing based predictive response signature and Cancer Subtyping Platform…
February 18, 2019
GeneCentric Therapeutics, Inc. collaborator Dr. Tracy Rose from the UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC presented at the Genitourinary Cancers Symposium today on: “Fibroblast growth factor receptor status and response…
January 3, 2019
CEO Dr. Myla Lai-Goldman named Executive Chairperson Durham, NC, January 3, 2019 -GeneCentric Therapeutics, Inc. today announced the appointment of Michael V. Milburn, PhD, as Chief Executive Officer and President and will…
December 10, 2018
Focus is on advancing cancer subtypes to predict disease progression and pursuing immune-biology related drug response biomarkers DURHAM, N.C., December 10, 2018 — GeneCentric Therapeutics, Inc. today announced that it has entered…
September 24, 2018
Company will develop Pancreatic Cancer Profiler based on technology to identify drug responders for therapeutic development DURHAM, N.C., September 24, 2018 — GeneCentric Therapeutics, Inc. today announced that the company has acquired…
September 10, 2018
GeneCentric Therapeutics, Inc. today announced the appointment of Michael V. Milburn, PhD, as Chief Scientific Officer (CSO). Dr. Milburn, who joins GeneCentric from Metabolon, Inc. where he was CSO, has more than…
August 17, 2018
GeneCentric Therapeutics’ CEO, Dr. Myla Lai-Goldman, will deliver a presentation at the Precision Medicine World Conference (PMWC) 2018 Duke University Program, September 24-25, entitled: “Delivering Greater Precision to Precision Medicine.” In an…
August 15, 2018
Dr. Myla Lai-Goldman, co-founder and CEO of GeneCentric Therapeutics, will co-Chair a panel at the Next Generation Diagnostics (Dx) Summit 2018, August 20-24 in Washington, DC titled: “Paths to Universal Drug-Diagnostics Co-Development.”…
Publications & Presentations
Comprehensive molecular profiling of lung adenocarcinoma
April 22, 2014
Comprehensive genomic characterization of squamous cell lung cancers
September 27, 2012
Events
No results found.